Regenxbio Inc (RGNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $505.18M
Last updated: Nov 17, 2026 at 11:05 AM ET
Regenxbio Inc (RGNX) Earnings: Report Dates and Results
Regenxbio (RGNX) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, Regenxbio reported EPS of -$0.62, above the -$1.35 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RGNX has an expected report date of Mar 3, 2027.
RGNX Earnings Call
The latest RGNX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, RGNX beat 18, missed 21 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $9.16M, down 69.2% from $29.73M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.62 | -$1.35 | -$1.63 - -$0.89 | +54.07% | Beat | N/A | 9 | 4 up, 2 down | Nov 5, 2026 | $9.16M |
| Jun 30, 2026 | $0.43 | $0.12 | -$1.23 - $0.73 | +258.33% | Beat | N/A | 7 | 0 up, 1 down | Aug 6, 2026 | $108.02M |
| Mar 31, 2026 | -$1.72 | -$1.41 | -$1.58 - -$1.23 | -21.99% | Miss | -1533.3% | 5 | 0 up, 4 down | May 14, 2026 | $6.39M |
| Dec 31, 2025 | -$1.30 | -$0.72 | -$1.65 - $0.43 | -80.71% | Miss | N/A | 8 | 0 up, 2 down | Mar 5, 2026 | $30.34M |
| Sep 30, 2025 | -$1.20 | -$1.30 | -$1.68 - -$0.89 | +7.69% | Beat | N/A | 6 | 0 up, 1 down | Nov 6, 2025 | $29.73M |
| Jun 30, 2025 | -$1.38 | -$1.13 | -$1.34 - -$0.75 | -22.12% | Miss | N/A | 6 | 2 up, 2 down | Aug 7, 2025 | $21.36M |
| Mar 31, 2025 | $0.12 | $0.49 | -$1.21 - $1.07 | -75.51% | Miss | N/A | 5 | 1 up, 0 down | May 12, 2025 | $89.01M |
| Dec 31, 2024 | -$1.01 | -$1.08 | -$1.33 - -$0.46 | +6.86% | Beat | N/A | 7 | 1 up, 0 down | Mar 13, 2025 | $21.21M |
| Sep 30, 2024 | -$1.17 | -$1.10 | -$1.28 - -$1.05 | -6.36% | Miss | N/A | 9 | 0 up, 0 down | Nov 6, 2024 | $24.20M |
| Jun 30, 2024 | -$1.05 | -$1.31 | -$1.41 - -$1.11 | +19.85% | Beat | N/A | 8 | 0 up, 0 down | Aug 1, 2024 | $22.30M |
| Mar 31, 2024 | -$1.34 | -$1.26 | -$1.50 - -$1.11 | -6.35% | Miss | N/A | 10 | 0 up, 0 down | May 8, 2024 | $15.62M |
| Dec 31, 2023 | -$1.43 | -$1.27 | -$1.52 - -$0.77 | -12.60% | Miss | N/A | 9 | 0 up, 0 down | Feb 27, 2024 | $22.21M |
| Sep 30, 2023 | -$1.41 | -$1.52 | -$1.74 - -$1.26 | +7.24% | Beat | N/A | 8 | 0 up, 0 down | Nov 8, 2023 | $28.91M |
| Jun 30, 2023 | -$1.66 | -$1.21 | -$1.55 - -$1.20 | -37.19% | Miss | N/A | 6 | 0 up, 0 down | Aug 2, 2023 | $19.98M |
| Mar 31, 2023 | -$1.53 | -$1.41 | -$1.77 - -$1.28 | -8.51% | Miss | N/A | 6 | 0 up, 0 down | May 3, 2023 | $19.14M |
| Dec 31, 2022 | -$1.38 | -$1.23 | -$1.67 - -$0.22 | -12.20% | Miss | -120.7% | 7 | 0 up, 0 down | Feb 28, 2023 | $31.34M |
| Sep 30, 2022 | -$1.75 | -$1.46 | -$1.56 - -$1.37 | -19.86% | Miss | N/A | 7 | 0 up, 0 down | Nov 3, 2022 | $26.51M |
| Jun 30, 2022 | -$1.58 | -$1.54 | -$1.64 - -$1.36 | -2.60% | Miss | N/A | 7 | 0 up, 1 down | Aug 3, 2022 | $32.65M |
| Mar 31, 2022 | -$1.79 | -$1.28 | -$1.39 - -$1.23 | -39.84% | Miss | N/A | 5 | 0 up, 0 down | May 4, 2022 | $22.22M |
| Dec 31, 2021 | $6.67 | $4.71 | -$1.31 - $9.39 | +41.61% | Beat | N/A | 6 | N/A | Mar 1, 2022 | $379.77M |
| Sep 30, 2021 | -$1.37 | -$1.12 | -$1.55 - $0.00 | -22.32% | Miss | -426.2% | 6 | N/A | Nov 2, 2021 | $30.77M |
| Jun 30, 2021 | -$1.36 | -$1.15 | -$1.70 - -$0.93 | -18.26% | Miss | N/A | 7 | N/A | Aug 9, 2021 | $22.04M |
| Mar 31, 2021 | -$1.20 | -$1.30 | -$1.63 - -$0.90 | +7.69% | Beat | N/A | 7 | N/A | May 5, 2021 | $37.77M |
| Dec 31, 2020 | -$1.24 | -$0.43 | -$1.70 - $4.10 | -188.37% | Miss | N/A | 7 | N/A | Mar 1, 2021 | $21.45M |
| Sep 30, 2020 | $0.42 | -$1.01 | -$1.36 - -$0.70 | +141.58% | Beat | N/A | 6 | N/A | Nov 4, 2020 | $98.91M |
| Jun 30, 2020 | -$0.91 | -$0.93 | -$1.07 - -$0.85 | +2.15% | Beat | N/A | 4 | N/A | Aug 6, 2020 | $16.57M |
| Mar 31, 2020 | -$1.08 | -$0.87 | -$1.02 - -$0.60 | -24.14% | Miss | N/A | 3 | N/A | May 7, 2020 | $17.64M |
| Dec 31, 2019 | -$0.72 | -$0.95 | -$1.19 - $0.25 | +24.21% | Beat | -754.5% | 5 | N/A | Feb 26, 2020 | $11.77M |
| Sep 30, 2019 | -$0.94 | -$0.24 | -$1.09 - -$0.24 | -291.67% | Miss | N/A | 5 | N/A | Nov 5, 2019 | $14.70M |
| Jun 30, 2019 | -$0.83 | -$0.77 | -$0.85 - $0.09 | -7.79% | Miss | -376.7% | 5 | N/A | Aug 7, 2019 | $7.88M |
| Mar 31, 2019 | -$0.89 | -$0.89 | -$0.98 - -$0.77 | 0.00% | In line | -129.3% | 4 | N/A | May 7, 2019 | $884000 |
| Dec 31, 2018 | $0.11 | -$0.34 | -$0.38 - -$0.31 | +132.35% | Beat | N/A | 4 | N/A | Feb 27, 2019 | $40.78M |
| Sep 30, 2018 | -$0.56 | -$0.81 | -$0.86 - $0.31 | +30.86% | Beat | N/A | 3 | N/A | Nov 7, 2018 | $5.31M |
| Jun 30, 2018 | $0.30 | $0.56 | $0.56 - $1.90 | -46.43% | Miss | N/A | 2 | N/A | Aug 8, 2018 | $40.03M |
| Mar 31, 2018 | $3.04 | $1.07 | -$0.88 - $1.63 | +184.11% | Beat | N/A | 5 | N/A | May 8, 2018 | $132.39M |
| Dec 31, 2017 | -$0.51 | -$0.82 | -$0.92 - -$0.67 | +37.80% | Beat | N/A | 5 | N/A | Mar 6, 2018 | $8.60M |
| Sep 30, 2017 | -$0.67 | -$0.73 | -$0.80 - -$0.66 | +8.22% | Beat | N/A | 4 | N/A | Nov 8, 2017 | $1.34M |
| Jun 30, 2017 | -$0.47 | -$0.80 | -$0.81 - -$0.69 | +41.25% | Beat | N/A | 2 | N/A | Aug 8, 2017 | N/A |
| Mar 31, 2017 | -$0.82 | -$0.76 | N/A | -7.89% | Miss | N/A | N/A | N/A | May 9, 2017 | $455000 |
| Dec 31, 2016 | -$0.74 | -$0.75 | N/A | +1.33% | Beat | N/A | N/A | N/A | Mar 7, 2017 | $1.70M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.76, after -$4.57 the year before. It was -$2.39 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.76 | N/A |
| Dec 31, 2024 | -$4.57 | N/A |
| Dec 31, 2023 | -$6.03 | N/A |
| Dec 31, 2022 | -$6.50 | -337.2% |
| Dec 31, 2021 | $2.74 | N/A |
| Dec 31, 2020 | -$2.81 | N/A |
| Dec 31, 2019 | -$3.38 | -217.0% |
| Dec 31, 2018 | $2.89 | N/A |
| Dec 31, 2017 | -$2.47 | N/A |
| Dec 31, 2016 | -$2.39 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,311 | 14 | |
| 2026Q1 | Mar 31, 2026 | 6,907 | 16 | |
| 2025Q4 | Dec 31, 2025 | 9,433 | 16 | |
| 2025Q3 | Sep 30, 2025 | 6,450 | 18 | |
| 2025Q1 | Mar 31, 2025 | 6,510 | 16 | |
| 2024Q4 | Dec 31, 2024 | 7,157 | 16 | |
| 2024Q3 | Sep 30, 2024 | 6,996 | 13 | |
| 2024Q2 | Jun 30, 2024 | 5,651 | 13 |
2026Q3 Earnings Call
Opening remarks
Patrick Christmas Chief Legal Officer Good morning, and thank you for joining us today. Earlier this morning, REGENXBIO released financial and operating results for the third quarter ended September 30, 2026. The press release is available on our website at www.regenxbio.com. Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the Risk Factors and the Management's Discussion and Analysis section of REGENXBIO's annual report on Form 10-K for the full year ended December 31, 2025, and comparable Risk Factors sections of REGENXBIO's quarterly report on Form 10-Q, which will be on file with the Securities and Exchange Commission and available on the SEC's website. Any information we provide on this conference call is provided only as of the date of this call, November 5, 2026, and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise. Please be advised that today's call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially. I'll now turn the call to Curran Simpson, President and CEO of REGENXBIO. Curran?
Curran Simpson President and CEO Thank you, Patrick, and good morning, everyone. Thank you for joining us today. This is an exciting time for REGENXBIO. We are on the cusp of multiple potential regulatory approvals and are preparing for commercialization. Joining me today are Dr. Steve Pakola, our Chief Medical Officer; and Mitch Chan, our Chief Financial Officer. I'll provide an update on our lead programs before turning it over to them for additional details. I'll begin with sura-vec, our potential first-in-class gene therapy for wet AMD and diabetic retinopathy developed in collaboration with AbbVie. Ahead of our top line pivotal readout expected later this year, last month, we hosted an investor event featuring five leading retina specialists. They discussed the opportunity for sura-vec to transform the wet AMD treatment paradigm. I want to highlight three key takeaways from the event. First, the unmet need in wet AMD remains significant. While anti-VEGF therapies are highly effective, the burden of frequent injections can be difficult for patients to sustain over time.
Frequently Asked Questions About RGNX
When is Regenxbio's next earnings date?
Regenxbio's next earnings report is expected for Mar 3, 2027.
Did RGNX beat earnings estimates last quarter?
Yes. Regenxbio reported EPS of -$0.62 for the quarter ended Sep 30, 2026, above the -$1.35 estimate, a 54.07% surprise.
What EPS do analysts expect from RGNX next quarter?
The consensus EPS estimate for Regenxbio for the quarter ending Dec 31, 2026 is -$1.01 from 13 analysts, with estimates from -$1.86 to $1.21.
How often does RGNX beat earnings estimates?
Regenxbio beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +15.83%.
RGNX pages: Overview, Earnings, Forecast, Financials, Competitors